Inhaled Treprostinil Improves FVC in IPF Phase 3 Trial: Steven D. Nathan, MD
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
Inhaled treprostinil has shown improvement in forced vital capacity (FVC) in a phase 3 trial for idiopathic pulmonary fibrosis (IPF). The trial's results indicate a positive outcome for this treatment approach. The study's findings suggest inhaled treprostinil may be beneficial for patients with IPF.